Next 10 |
home / stock / srpt / srpt articles
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Fortinet, Inc. (NASDAQ:FTNT) is not his favorite. He added that we own Palo...
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates ...
Sarepta Therapeutics (NASDAQ:SRPT) has outperformed the market over the past 10 years by 8.61% on an annualized basis producing an average annual r...
Sarepta Therapeutics (NASDAQ:SRPT) has outperformed the market over the past 10 years by 7.68% on an annualized basis producing an average annual r...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
These large-cap stocks were the best performers in the last week. Are they in your portfolio? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares incr...
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite moving lower on Friday. The Dow traded down 0.01% to 39,133.99 while ...
Shares of Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) fell sharply during Friday's session after the company announced pricing of $6.0...
Shares of Catalent Inc (NYSE:CTLT), which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an aver...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
2024-07-08 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-06 08:00:00 ET On June 20, the Food and Drug Administration (FDA) gave Sarepta Therapeutics (NASDAQ: SRPT) exactly what it wanted. The agency upgraded the status of its gene therapy for Duchenne muscular dystrophy (DMD), Elevidys, from an accelerated approval to a full appro...